6869 On Other Exchanges
Symbol
Exchange
6869 is not on other exchanges.

sysmex corp (6869) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYSMEX CORP (6869)
\

Related News

No related news articles were found.

sysmex corp (6869) Related Businessweek News

No Related Businessweek News Found

sysmex corp (6869) Details

Sysmex Corporation, together with its subsidiaries, engages in the development, manufacture, sale, and export/import of diagnostic instruments, reagents, and related software for the use in hematology, urinalysis, immunochemistry, clinical chemistry, and hemostasis worldwide. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; systems for high-volume testing in labs; and hematology analyzers for animals. The company also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for to test for liver fibrosis progression and atopic dermatitis; and instruments for determining the activity of blood hemostasis, as well as support services for hemostasis products. In addition, it offers sales and support services for automated clinical chemistry analyzers; systems that to test for lymph node metastasis; and assay services, such as Curebest 95GC Breast, a service for research use to determine expression levels of 95 cancer-related gene types. It serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

6,964 Employees
Last Reported Date: 06/23/17
Founded in 1968

sysmex corp (6869) Top Compensated Officers

Chairman of the Managing Board, CEO & Preside...
Total Annual Compensation: ¥188.0M
Compensation as of Fiscal Year 2017.
sysmex corp
Kyoto University, SRL Inc., Tsubakimoto Chain Co., Ltd., Sysmex Corporation, Asklep Inc., Shimadzu Corporation, Fujitsu Ltd., and SCREEN Holdings Co., Ltd. to Build New Industry-Academic Collaboration Model

Kyoto University, SRL Inc., Tsubakimoto Chain Co., Ltd., Sysmex Corporation, Asklep Inc., Shimadzu Corporation, Fujitsu Ltd., and SCREEN Holdings Co., Ltd. have decided to build a new industry-academic collaboration model that makes use of each members’ research and business bases, aimed at contributing to developing innovative medicine in Japan. Of these, Kyoto University will carry out one-stop bio-resource projects via the Clinical Bio-resource Center that was established inside its University Hospital, while the seven companies will newly establish KBBM Co., Ltd. to promote the project. Both sides will tackle new, 'industry-in-the-academia' industry-academia alliances to deliver even more effective and safe drugs and treatment methods even more quickly to the patients. The new company was named 'KBBM' with the hope of building a bridge of innovative medicine from Kyoto (Kyoto Bridge for Breakthrough Medicine).

Sysmex Corporation Announces Management Changes; Plans to Establish the New LS Business Development Department

Sysmex Corporation announced its decision to implement organizational and personnel changes, effective April 1, 2018. The company will establish the new LS Business Development Department to oversee global activities in the LS business, from drafting strategies to launching products. The company also announced promotion of John Kershaw as Senior Executive Officer from Executive Officer. The company announced retirement of Hiroshi Nagao. The company also announced Yukio Nakajima to be Member of the Managing Board and Senior Executive Officer Senior Managing Director CFO In charge of; Corporate Business Planning Office Corporate Communication Div. Corporate Business Administration Div. Human Resources Div., General Affairs Div., Corporate Executive Office, Sysmex Business Support Co. Ltd., Sysmex Harmony Co. Ltd. from Member of the Managing Board and Senior Executive Officer Senior Managing Director In charge of; Corporate Business Planning Office, Corporate Communication Div., Corporate Business Administration Div., Human Resources Div., General Affairs Div., Corporate Executive Office, Sysmex Business Support Co. Ltd., Sysmex Harmony Co. Ltd. Kaoru Asano as Member of the Managing Board and Senior Executive Officer Senior Managing Director COO LS Business Unit and CTO In charge of; Technology Strategy Div., Central Research Laboratories, Technology Development Div., Intellectual Property Div., LS Business Div., Clinical Innovation Div., MR Business Development Div., Medicaroid Corporation, Sysmex Engineering Co.,Ltd., RIKEN GENESIS CO., LTD., Sysmex Inostics GmbH, Oxford Gene Technology IP Limited, Vice President of Medicaroid Corporation Director of RIKEN GENESIS CO., LTD. from Member of the Managing Board and Senior Executive Officer Senior Managing Director In charge of; Technology Strategy Div. Central Research Laboratories Technology Development Div. Intellectual Property Div. LS Business Div. Clinical Innovation Div. MR Business Development Div. Medicaroid Corporation Sysmex Engineering Co.,Ltd. RIKEN GENESIS CO., LTD. Sysmex Inostics GmbH, Oxford Gene Technology IP Limited, Vice President of Medicaroid Corporation, Director of RIKEN GENESIS CO., LTD. Kenji Tachibana to Member of the Managing Board and Senior Executive Officer Senior Managing Director COO IVD Business Unit In charge of; Business Strategy Development Div., HU Business Development Div., ICH Business Development Div., Engineering 1 Div., Engineering 2 Div., Sysmex Partec GmbH HYPHEN BioMed, SAS, Sysmex Wuxi Co. Ltd. from Member of the Managing Board and Senior Executive Officer Senior Managing Director In charge of; Business Strategy Development Div. HU Business Development Div. ICH Business Development Div. Engineering 1 Div. Engineering 2 Div. Sysmex Partec GmbH HYPHEN BioMed, SAS Sysmex Wuxi Co. Ltd. Hiroshi Kanda to Senior Executive Officer Deputy in charge of; HU Business Development Div. ICH Business Development Div. HYPHEN BioMed, SAS Sysmex Wuxi Co. Ltd. from Senior Executive Officer Deputy in charge of; HU Business Development Div. ICH Business Development Div. HYPHEN BioMed, SAS Sysmex Wuxi Co. Ltd. Executive Vice President of ICH Business Development Div. John Kershaw to Senior Executive Officer Chairman, Sysmex America Inc. Deputy to COO IVD Business Unit Special Projects and Missions from Executive Officer Chairman, Sysmex America Inc. Deputy in charge of; Business Strategy Development Div. HU Business Development Div. ICH Business Development Div. Engineering 1 Div. Engineering 2 Div. Ikuo Otani to Executive Officer Deputy in charge of; Engineering 1 Div. Engineering 2 Div. Technology HR Development Dept. Development Administration Dept. from Executive Officer Deputy in charge of; Engineering 1 Div. Engineering 2 Div. Juergen Schulze to Executive Officer Chairman, Sysmex Europe GmbH from Executive Officer President and CEO, Sysmex Europe GmbH. Mamoru Kubota to Executive Officer Deputy in charge of; LS Business Div. Clinical Innovation Div. LS Business Development Dept. RIKEN GENESIS CO., LTD. Sysmex Inostics GmbH Oxford Gene Technology IP Limited from Executive Officer Executive Vice President of LS Business Div. Kensuke Iizuka to Executive Officer Deputy in charge of; Corporate Business Planning Office Corporate Communication Div. Corporate Business Administration Div. Human Resources Div. General Affairs Div. Corporate Executive Office Sysmex Business Support Co. Ltd. Sysmex Harmony Co. Ltd. Executive Vice President of Corporate Business Administration Div. from Executive Officer Deputy in charge of; Corporate Business Planning Office Corporate Communication Div. Human Resources Div. General Affairs Div. Corporate Executive Office Sysmex Business Support Co. Ltd. Sysmex Harmony Co. Ltd. Executive Vice President of Corporate Executive Office.

Sysmex Announces Consolidated Earnings Results for the Nine Months of Fiscal Year Ended March 31, 2018; Provides Financial Forecast for the Year Ending March 31, 2018

Sysmex announced consolidated earnings results for the nine months of fiscal year ended March 31, 2018. For the period, the company reported Net sales were JPY 202.5 billion. The growth was 12%. Operating income was JPY 44.5 billion. It went up by 13.8%. Profit attributable to owners of the parent were JPY 30.5 billion. It went down by 4.4%. Net sales increased in all regions. Operating income increased due to the profit -- gross profit growth by the sales increase. Tax rate was 32.7%. Operating income increased due to the gross profit increase by the sales growth and SG&A increases. Operating income were JPY 3.8 billion, up by 53.1%. Operating profit were JPY 4.35 billion, went up by 17.8%. The FX impact was JPY 9.09 billion on the sales on positive, and operating income positive impact was JPY 1.62 billion, and net income went down due to the tax treaty revision with Germany last year. Profit attributable to owners of the parent was JPY 30,555 million against JPY 31,967 million a year ago. Diluted earnings per share was JPY 146.37 per share against JPY 153.19 per share a year ago. Profit before tax was JPY 45,130 million against JPY 37,194 million a year ago. Net cash provided by operating activities was JPY 34,226 million against JPY 17,900 million a year ago. Purchase of property, plant and equipment was JPY 8,587 million against JPY 8,199 million a year ago. Purchase of intangible assets was JPY 6,953 million against JPY 5,474 million a year ago. The company provided financial forecast for the year ending March 31, 2018. For the year, The company expects to report net sales of JPY 280,000 million, Operating profit of JPY 58,000 million, Profit before tax of JPY 58,000 million, Profit attributable to owners of the parent of JPY 41,500 and basic earnings per share of JPY 199.24 per share. The company expects to pay a dividend of JPY 30 per share for the year ending March 31, 2018 against JPY 30 per share a year ago.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

6869 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 6869.
View Industry Companies
 

Industry Analysis

6869

Industry Average

Valuation 6869 Industry Range
Price/Earnings 52.3x
Price/Sales 7.5x
Price/Book 8.7x
Price/Cash Flow 52.4x
TEV/Sales 7.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SYSMEX CORP, please visit www.sysmex.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.